MEDIVIR, INTERIM REPORT, 1 January – 31 March 2006

• MIV-210 produced promising results against hepatitis B in a study conducted at INSERM in Lyon, France. • Medivir acquired all product rights to the Cathepsin S project. • A CD (candidate drug), MIV-170, has been designated on Medivir's HIV NNRTI program. • Consolidated net sales were SEK 9.5 (13.7) m in the period 1 January - 31 March 2006. • The loss after tax as SEK -50.0 (-36.2) m; earnings per share were SEK -3.87 (-2.81). FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Annual General Meeting will be held on today’s date, from 3 p.m. The Six-month Interim Report will be published on 10 July 2006 The Nine-month Interim Report will be published on 23 October 2006 Medivir’s financial reports are available on its Website, www.medivir.com from these dates under the ‘Investor/Media’ heading.